News briefs from Threshold, Merck KGaA and GSK

18 September 2012

US biotech firm Threshold Pharmaceuticals (Nasdaq: THLD) said yesterday that data from a Phase IIb trial of TH-302 in patients with advanced pancreatic cancer will be presented at the European Society for Medical Oncology, Austria, September 28 to October 2, 2012. New finding on overall survival indicate that patients treated with gemcitabine alone had a median overall survival of 6.9 months versus 9.2 months with TH-302 340 mg/m2 + gemcitabine (HR: 0.955, 95% CI: 0.67-1.37, p=0.800) and 8.7 months with TH-302 240 mg/m2 + gemcitabine (HR: 0.960, 95% CI: 0.67-1.38, p=0.827).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK